Strategies to Evade Effective Antitumor Responses
Tumor progression results from a disrupted regulation of cell growth as well as from the failure of the host to mount an efficient antitumor immune response. 5 and hepatocellular carcinoma. 6 Taken together, these observations plead in favor of a substantial role of Tregs in oncogenesis and tumor progression, which may be related to their robust immunosuppressive functions.
Another effective strategy for malignant cells to evade antitumor responses consists in the direct secretion of immunosuppressive factors such as IL-10 and TGFβ, a process that may be related to FOXP3 expression by cancer cells. 7 Whether the expression of these cytokines truly provides tumors with the ability to evade immune responses remains to be elucidated. In vitro, FOXP3 expression by tumor cells has been correlated with the inhibition of T-cell proliferation, indicating that cancer cells may share growthsuppressive effects with Tregs and that mimicking Tregs functions may represent a novel mechanism of immune evasion.
Correlation between FOXP3 Expression and Tumor Progression
In various solid tumors, including ovarian and pancreatic cancer, a high density of tumor-infiltrating FOXP3 + Tregs has been linked with poor disease outcome. 5 Conversely, no significant association between the absolute number of tumorinfiltrating FOXP3 + T cells and prognosis was established in several studies involving CRC patients. In addition, some studies suggest that a high frequency of tumorinfiltrating FOXP3 + Tregs may de facto be associated with a favorable, rather than a dismal, prognosis. 8 Recent clinical data have provided the first evidence in support of FOXP3 expression by multiple distinct cancer cells. 9 However, the biological significance of FOXP3 expression by CRC cells remains unknown.
We have recently evaluated FOXP3 expression by tumor-infiltrating Tregs and CRC cells in patients affected by different stages of the disease (UICC I-IV) and investigated its long-term prognostic significance. 10 The analysis of CD4, CD25, FOXP3, IL-10 and TGFβ expression profiles suggest that CD4 and CD25 are expressed to significantly higher levels in the transcription factor forkhead box P3 (FOXP3) has been identified as a marker of CD4 + CD25 + regulatory t cells and is a key determinant of their immunosuppressive functions. FOXP3 has indeed been shown to limit antitumor immune responses during tumor progression. In addition, by expressing FOXP3, tumor cells may evade effector t-cell responses.
would be capable to downregulate antitumor effector T-cell responses. The overall survival of patients exhibiting low or high levels of tumor-infiltrating FOXP3 + Tregs in comparison to that of patients displaying low or high FOXP3 levels on malignant cells suggested that FOXP3 expression by cancer cells may constitute a prognostic factor. Indeed, CRC patients exhibiting high FOXP3 expression levels on cancer cells had a worse prognosis than patients with low FOXP3 levels. Conversely, no significant correlation was observed between the expression pattern of FOXP3 on tumor-infiltrating Tregs and prognosis. 10 In conclusion, the expression of FOXP3 by cancer cells, resulting in the secretion of immunosuppressive cytokines such as IL-10 and TGFβ into the tumor microenvironment, may allow them to evade effector T-cell responses and hence progress (Fig. 1) . In addition, FOXP3 expression by cancer cells appears as an independent prognostic factor for CRC patients.
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patients analyzed in this respect. We have observed that the expression of FOXP3 by cancer cells was significantly correlated with that of IL-10 and TGFβ. 10 We 
